Top Medical Stocks To Own For 2018

&l;p&g;&l;img class=&q;dam-image ap size-large wp-image-ba4ef5ff096448cd8ab8d96d86dd3669&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/ba4ef5ff096448cd8ab8d96d86dd3669/960×0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; Diana Briggs, whose son, Ryan Briggs suffers from intractable epilepsy, leaves CY+ Medical marijuana Dispensary with a bag containing the medicine for him after being the first patron to buy a prescribed medical marijuana product at a dispensary on Thursday, Feb. 15, 2018 in Butler, Pa.(AP Photo/Keith Srakocic)

While it&s;s not a done deal until Congress formally approves it and President Trump signs it, the &l;a href=&q;https://www.politico.com/f/?id=00000162-4b0d-de1c-abfe-6bbd26030001&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q; target=&q;_blank&q;&g;budget proposal&l;/a&g; agreed to by Congressional leaders last night&a;nbsp;would keep medical cannabis protections in effect through September 30, as fellow &l;em&g;Forbes&l;/em&g;&a;nbsp;contributor Tom Angell &l;a href=&q;https://www.forbes.com/sites/tomangell/2018/03/21/congress-protects-medical-marijuana-from-jeff-sessions-in-new-federal-spending-bill/#1d62e0b43575&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q;&g;noted last night&l;/a&g;. As I shared two months ago, the rescission of the Cole Memo in early January by Attorney General Jeff Sessions had left the industry &l;a href=&q;https://www.forbes.com/sites/alanjbrochstein/2018/01/21/cannabis-stock-investors-should-pay-attention-to-the-u-s-federal-policy-change/#39e7e0273788&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q;&g;vulnerable to federal enforcement of the Controlled Substances Act&l;/a&g;&a;nbsp;if the Rohrabacher-Blumenauer Amendment were not to be included in the next budget. My caution on cannabis stocks has been warranted, as the &l;a href=&q;https://www.newcannabisventures.com/cannabis-stock-index/&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q; target=&q;_blank&q;&g;Global Cannabis Stock Index&l;/a&g; has sold off more than 27% over the past two months since my warning.

Top Medical Stocks To Own For 2018: Performant Financial Corporation(PFMT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Performant Financial Corporation (NASDAQ: PFMT) were down 29 percent to $2.20. Performant Financial is expected to release Q1 earnings on May 8.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Check-Cap Ltd. (NASDAQ: CHEK) shares dipped 47.8 percent to $4.60. Check-Cap priced its upsized underwritten offering of public units at $5.50 per unit.
    VivoPower International PLC (NASDAQ: VVPR) shares fell 41.5 percent to $2.57.
    Universal Electronics Inc. (NASDAQ: UEIC) dropped 35.1 percent to $29.50 after the company posted downbeat quarterly results.
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) dropped 34.8 percent to $3.75 after climbing 155.56 percent on Thursday.
    Integrated Media Technology Limited (NASDAQ: IMTE) fell 25.2 percent to $24.01 after surging 46.29 percent on Thursday.
    Fluor Corporation (NYSE: FLR) dropped 22.5 percent to $45.73 after the company reported downbeat earnings for its first quarter and lowered its profit outlook for the year.
    AMN Healthcare Services, Inc (NYSE: AMN) shares fell 19.6 percent to $52.075 following Q1 earnings.
    Adverum Biotechnologies, Inc. (NASDAQ: ADVM) shares declined 18.1 percent to $5.20. Adverum Biotech disclosed that its CEO Amber Salzman is stepping down.
    Newater Technology, Inc. (NASDAQ: NEWA) dropped 17.2 percent to $12.83.
    Basic Energy Services, Inc. (NYSE: BAS) fell 17.2 percent to $13.65 following Q1 results.
    Xperi Corporation (NASDAQ: XPER) declined 15.8 percent to $19.40 after announcing Q1 results.
    Sharing Economy International Inc. (NASDAQ: SEII) shares fell 15.1 percent to $3.649 after climbing 22.16 percent on Thursday.
    Performant Financial Corporation (NASDAQ: PFMT) dropped 14.2 percent to $2.65.
    Gogo Inc. (NASDAQ: GOGO) shares fell 13.2 percent to $8.32 after the company reported Q1 results and disclosed that it is withdrawing its FY18 outlook for adjusted EBITDA, airborne cash capex, airborne equipment inventory purchases and free cash flow.
    Technical Communications Corporation (NASDAQ: TCCO) dropped 12.2 percent to $5.05.
    Web.com Group, Inc. (NASDAQ: WEB) fell 9.7 percent

Top Medical Stocks To Own For 2018: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By Lisa Levin] Companies Reporting Before The Bell
    Celgene Corporation (NASDAQ: CELG) is projected to report quarterly earnings at $1.96 per share on revenue of $3.46 billion.
    Aon plc (NYSE: AON) is expected to report quarterly earnings at $2.8 per share on revenue of $2.93 billion.
    American Axle & Manufacturing Holdings, Inc. (NYSE: AXL) is estimated to report quarterly earnings at $0.81 per share on revenue of $1.75 billion.
    Alibaba Group Holding Limited (NYSE: BABA) is expected to report quarterly earnings at $0.88 per share on revenue of $9.27 billion.
    LifePoint Health, Inc. (NASDAQ: LPNT) is projected to report quarterly earnings at $1.13 per share on revenue of $1.62 billion.
    V.F. Corporation (NYSE: VFC) is estimated to report quarterly earnings at $0.65 per share on revenue of $2.90 billion.
    Newell Brands Inc. (NYSE: NWL) is expected to report quarterly earnings at $0.26 per share on revenue of $3.05 billion.
    Titan International, Inc. (NYSE: TWI) is projected to report quarterly earnings at $0.04 per share on revenue of $407.27 million.
    Boise Cascade Company (NYSE: BCC) is expected to report quarterly earnings at $0.45 per share on revenue of $1.09 billion.
    Cheniere Energy, Inc. (NYSE: LNG) is estimated to report quarterly earnings at $0.39 per share on revenue of $1.59 billion.
    Cboe Global Markets, Inc. (NASDAQ: CBOE) is projected to report quarterly earnings at $1.24 per share on revenue of $308.05 million.
    ITT Inc. (NYSE: ITT) is estimated to report quarterly earnings at $0.73 per share on revenue of $683.96 million.
    Fred's, Inc. (NASDAQ: FRED) is expected to report quarterly loss at $0.19 per share on revenue of $551.00 million.
    Virtu Financial, Inc. (NASDAQ: VIRT) is projected to report quarterly earnings at $0.52 per share on revenue of $288.31 million.
    Cheniere Energy Partners, L.P. (NYSE: CQP) is expected to report quarterly earnings at $0.57 per share on revenue of $1.38 billion.
    Genesis Energy, L.P
  • [By WWW.THESTREET.COM]

    Originally published Nov. 17 at 3:41 p.m. EDT

    The consideration of the contrary has been a theme all week. And here in ” Don’t Run With the Crowd: Embrace the Contrary.”   Miami madness (of a real estate kind)   Mark Grant is scared by our currency’s strength.   Danielle on scenarios.   Boockvar to subscriber Bad Golfer!   JC Penney ( JCP) short puts–a 100% win. (Shorting options frequently ends differently!)   Just say no to closed-end muni-bond funds.   DRYS is all wet.   Could iPhone manufacturing be coming back home?   On inflation breakevens–a picture that speaks volumes.   The market moved higher from the “get go”–in large measure it seems to be a response to the better economic data this morning.   At 3 p.m. stocks were near the day’s highs.   I shorted The Cisco Kid last night. Sticking with this short rental. I added to my ProShares UltraShort S&P500 ETF ( SDS) long (growing ever larger). My net short exposure–is now between small and medium-sized at the close. The U.S. dollar, as discussed above, continued to rip higher against the euro. I am concerned. Mark Grant is concerned. The market is not concerned. The price of crude oil (down $0.20) settled lower after yesterday’s robust gains. Gold fell $9 as it continues to break down–closing in on $1,200. Ag commodities: wheat up $0.07, corn up $0.04, soybeans up $0.05 and oats up $0.02. Lumber up $7 following the big housing number this morning. Bonds schmeissed … iShares Barclays 2

  • [By Keith Speights]

    That’s a pretty good definition of leadership, but it’s not an easy one to accomplish. However, the CEOs of Celgene (NASDAQ:CELG), Cognizant Technology Solutions (NASDAQ:CTSH), General Electric (NYSE:GE), MasterCard (NYSE:MA), and Texas Instruments (NASDAQ:TXN) have been able to achieve this translation very well.

  • [By Keith Speights]

    Smart investors will be ready to take advantage of a market pullback, whenever it comes and offers discount prices on great stocks. Three drug stocks appear to be excellent choices to buy on a dip: AbbVie (NYSE:ABBV), Allergan (NYSE:AGN), and Celgene (NASDAQ:CELG). Here’s why.

  • [By Ben Levisohn]

    After years of rising and falling in tandem, the biotech sector is all about stock picking now. Credit Suisse analyst Alethia Young and team, for instance, upgraded Regeneron Pharmaceuticals (REGN), and added Celgene (CELG) to its Focus List today. But Amgen (AMGN) wasn’t so lucky as Young cut it to Neutral from Outperform. She explains why:

Top Medical Stocks To Own For 2018: Vermillion, Inc.(VRML)

Advisors’ Opinion:

  • [By Alex McGuire]

    Here’s a list of the top 10 penny stocks to watch in March, which includes the biggest gainers last month…

    Penny StockCurrent Stock PriceFebruary 2017 ReturnZosano Pharma Corp. (Nasdaq: ZSAN)$2.56+123.3%Bellerophon Therapeutics Inc. (Nasdaq: BLPH)$1.25+113.8%Peregrine Pharmaceuticals (Nasdaq: PPHM)$0.59+101.7%Galectin Therapeutics Inc. (Nasdaq: GALT)$1.79+91.9%Bioanalytical Systems Inc. (Nasdaq: BASI)$1.58+90.6%CymaBay Therapeutics Inc. (Nasdaq: CBAY)$3.50+89.8%Vermillion Inc. (Nasdaq: VRML)$2.56+86.3%Naked Brand Group Inc.(Nasdaq:NAKD)$2.16+76%Eyegate Pharmaceuticals Inc. (Nasdaq: EYEG)$2.63+73.9%Benitec Biopharma Ltd. (Nasdaq ADR: BNTC)$2.60+59.9%

    The best-performing penny stock – Zosano Pharma Corp. – soared an incredible 123.3% from Feb. 1 to Feb. 28. To put those gains into perspective, that’s more than five times the S&P 500’s 23% climb in the last 12 months.

Top Medical Stocks To Own For 2018: Transdigm Group Incorporated(TDG)

Advisors’ Opinion:

  • [By Ben Levisohn]

    TransDigm Group (TDG) soared to the top of the S&P 500 today after beating earnings and sales forecasts.

    Agence France-Presse/Getty Images

    TransDigm gained 6.5% to $245.88 today, while the S&P 500 finished little changed at2,293.08.

    TransDigm reported a profit of $2.57, beating forecasts for$2.47, on sales of $814 million, topping the Street consensus for $804.5 million.

    TransDigm’s market capitalization rose to $13.1 billion today from $12.3 billion yesterday.

  • [By Mitchell Clark]

     This firm is not a household name. This Cleveland-based company, in the aerospace parts business, has approximately $12.0 billion in market capitalization on the stock market.

    TransDigm Group Incorporated (NYSE:TDG) doesn’t pay a regular dividend, but often pays out one-time, special dividends. In the past, they’ve been pretty hefty.

    Selling pumps, motors, power systems, and basically anything you can image that’s part of an aircraft, TDG’s been growing its financial results at a good clip.

  • [By Ben Levisohn]

    TransDigm Group (TDG) tumbled to the bottom of the S&P 500 today after Citron Research doubled down on its assertion that the company is a manufacturing version of Valeant Pharmaceuticals International (VRX).

    Agence France-Presse/Getty Images

    TransDigm Groupdropped 4.2% to $231.37, while the S&P 500 rose 0.3% to 2,372.60.

    From Citron’s report on TransDigm:

    Citron predicts that after this report makes its rounds, TransDigms (NYSE:TDG) days of exploiting and deceiving the Federal Government are numbered.

    Valeant Pharmaceuticals has recently hit prices lower than some ever thought was imaginable. As Citron observes today, at $12 per share, that stock is down over 95% from its highs just months prior to Citrons reporting on Philidor. The questions then turn to: How did so many smart people get it so wrong? and When could this possibly happen again?”

    While we are sure there will be many books written on these questions, we can narrow it down to a small checklist. The smart money got Valeant wrong by:

    Disregarding a roiling political climate disrupting “business as
    usual” Underestimating the financial frailty of a roll up Discounting the dangers of a small customer base (PBMs) Putting too much trust in the companys CEO…

    All points in the above checklist apply directly to TransDigm.

    TransDigm Group’s market capitalization fell to $12.2 billion today from $12.8 billion yesterday. It reported net income of $583 million on sales of $3.2 billion in 2016.

  • [By Ben Levisohn]

    TransDigm (TDG) sunk to the bottom of the S&P 500 today after its earnings topped the Street consensus but its guidance disappointed.

    Shares of TransDigm fell 7.1% to $$252.96 today, while the S&P 500 finished little changed.

    TransDigm reported a profit of $3.29 a share, better than the $3.20 expect by analysts, on sales of$875.2 million, below forecasts for $884.26 million. Worse still, the airplane-part manufacturer said it would earn $11.84 to $12.12 a share in fiscal 2017, below forecasts for$12.80.

    TransDigm’s market cap fell to $13.5 billion today, from $14.5 billion on Friday.

  • [By Lee Jackson]

    Transdigm Group Inc. (NYSE: TDG) had a director at the company step in and buy stock in a big way last week. That director purchased a total of 91,000 shares of the stock at prices ranging from $247.16 to $247.89. The total for the trade came in near $22.7 million.The company designs, produces and supplies aircraft components in the United States. Its stock closed trading last Friday at $251.488.

  • [By Lee Jackson]

    Warren Buffett and Berkshire Hathaway were big buyers this week, as they added shares of aircraft components maker Transdigm Group Inc. (NYSE: TDG), forwhich they also serve as a director. Berkshire Hathaway bought 104,967 shares of the stock at prices that ranged from $231.18 to $234.40 per share. The total for the trade came in at a massive $25 million. The shares closed trading last Friday at $240.05, so the timing looks good. The 52-week trading range for the stock is $214.65 to $294.38. The Wall Street consensus price target is pegged at $295.24.

Top Medical Stocks To Own For 2018: CVD Equipment Corporation(CVV)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Wednesday, our Under the Radar Moversnewsletter suggested small cap materials and coatings stock CVD Equipment Corporation (NASDAQ: CVV) as a short/bearish trade:

  • [By Jim Robertson]

    At the beginning of the week, our Under the Radar Moversnewsletter suggestedsmall cap industrial machinery stock CVD Equipment Corporation (NASDAQ: CVV) as a long/bullish trade:

Top Medical Stocks To Own For 2018: Rackspace Hosting Inc(RAX)

Advisors’ Opinion:

  • [By Monica Gerson]

    Rackspace Hosting, Inc. (NYSE: RAX) reported better-than-expected earnings for the first quarter, but the company missed analysts’ sales estimates. Rackspace shares dropped 7.72 percent to $20.80 in the after-hours trading session.

Leave a Reply

Your email address will not be published. Required fields are marked *